##gff-version 3								
##gvf-version 1.10								
##species https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=2697049								
#seqid	#source	#type	#start	#end	#score	#strand	#phase	#attributes
NC_045512.2	.	snp	241	241	.	+	.	ID=ID_0;Name=g.C-25T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=36;dp=36;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C-25T;aa_name=;hgvs_nt=NC_045512.2:g.25C>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	405	405	.	+	.	ID=ID_1;Name=K47R;alias=K47R;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=0;ao=35;dp=35;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A140G;aa_name=p.K47R;hgvs_nt=NC_045512.2:g.140A>G;hgvs_aa=YP_009724389.1:p.Lys47Arg;hgvs_alias=YP_009724389.1:Lys47Arg;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	514	514	.	+	.	ID=ID_2;Name=M85_V86del;alias=M85_V86del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=TGTTATG;Variant_seq=T;nt_name=g.253_258delATGGTT;aa_name=p.M85_V86del;hgvs_nt=NC_045512.2:g.253_258del;hgvs_aa=YP_009724389.1:p.Met85_Val86del;hgvs_alias=YP_009724389.1:Met85_Val86del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	655	655	.	+	.	ID=ID_3;Name=G130G;alias=G130G;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=35;ao=1;dp=36;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A390G;aa_name=p.G130G;hgvs_nt=NC_045512.2:g.390A>G;hgvs_aa=YP_009724389.1:p.Gly130Gly;hgvs_alias=YP_009724389.1:Gly130Gly;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.027777777777777776;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	670	670	.	+	.	ID=ID_4;Name=S135R;alias=S135R;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=G;nt_name=g.T405G;aa_name=p.S135R;hgvs_nt=NC_045512.2:g.405T>G;hgvs_aa=YP_009724389.1:p.Ser135Arg;hgvs_alias=YP_009724389.1:Ser135Arg;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	675	675	.	+	.	ID=ID_5;Name=G137D;alias=G137D;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=G;Variant_seq=A;nt_name=g.G410A;aa_name=p.G137D;hgvs_nt=NC_045512.2:g.410G>A;hgvs_aa=YP_009724389.1:p.Gly137Asp;hgvs_alias=YP_009724389.1:Gly137Asp;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	685	685	.	+	.	ID=ID_6;Name=K141_F143del;alias=K141_F143del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=34;ao=3;dp=37;sample_size=37;Reference_seq=AAAGTCATTT;Variant_seq=A;nt_name=g.421_429delAAGTCATTT;aa_name=p.K141_F143del;hgvs_nt=NC_045512.2:g.421_429del;hgvs_aa=YP_009724389.1:p.Lys141_Phe143del;hgvs_alias=YP_009724389.1:Lys141_Phe143del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.08108108108108109;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	792	792	.	+	.	ID=ID_7;Name=E176A;alias=E176A;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp1;mat_pep_desc=nsp1%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:1..180;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=A;Variant_seq=C;nt_name=g.A527C;aa_name=p.E176A;hgvs_nt=NC_045512.2:g.527A>C;hgvs_aa=YP_009724389.1:p.Glu176Ala;hgvs_alias=YP_009724389.1:Glu176Ala;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	920	920	.	+	.	ID=ID_8;Name=L219L;alias=L39L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=28;ao=9;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C655T;aa_name=p.L219L;hgvs_nt=NC_045512.2:g.655C>T;hgvs_aa=YP_009724389.1:p.Leu219Leu;hgvs_alias=YP_009724389.1:Leu39Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.24324324324324326;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	1087	1087	.	+	.	ID=ID_9;Name=V274V;alias=V94V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A822G;aa_name=p.V274V;hgvs_nt=NC_045512.2:g.822A>G;hgvs_aa=YP_009724389.1:p.Val274Val;hgvs_alias=YP_009724389.1:Val94Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	1126	1126	.	+	.	ID=ID_10;Name=R287R;alias=R107R;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=G;Variant_seq=A;nt_name=g.G861A;aa_name=p.R287R;hgvs_nt=NC_045512.2:g.861G>A;hgvs_aa=YP_009724389.1:p.Arg287Arg;hgvs_alias=YP_009724389.1:Arg107Arg;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	1288	1288	.	+	.	ID=ID_11;Name=C341C;alias=C161C;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C1023T;aa_name=p.C341C;hgvs_nt=NC_045512.2:g.1023C>T;hgvs_aa=YP_009724389.1:p.Cys341Cys;hgvs_alias=YP_009724389.1:Cys161Cys;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	1670	1670	.	+	.	ID=ID_12;Name=L469F;alias=L289F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=0;ao=36;dp=36;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C1405T;aa_name=p.L469F;hgvs_nt=NC_045512.2:g.1405C>T;hgvs_aa=YP_009724389.1:p.Leu469Phe;hgvs_alias=YP_009724389.1:Leu289Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	1711	1711	.	+	.	ID=ID_13;Name=A482A;alias=A302A;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T1446C;aa_name=p.A482A;hgvs_nt=NC_045512.2:g.1446T>C;hgvs_aa=YP_009724389.1:p.Ala482Ala;hgvs_alias=YP_009724389.1:Ala302Ala;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	1848	1848	.	+	.	ID=ID_14;Name=S528L;alias=S348L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C1583T;aa_name=p.S528L;hgvs_nt=NC_045512.2:g.1583C>T;hgvs_aa=YP_009724389.1:p.Ser528Leu;hgvs_alias=YP_009724389.1:Ser348Leu;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	1890	1890	.	+	.	ID=ID_15;Name=R542H;alias=R362H;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=G;Variant_seq=A;nt_name=g.G1625A;aa_name=p.R542H;hgvs_nt=NC_045512.2:g.1625G>A;hgvs_aa=YP_009724389.1:p.Arg542His;hgvs_alias=YP_009724389.1:Arg362His;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	1912	1912	.	+	.	ID=ID_16;Name=S549S;alias=S369S;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C1647T;aa_name=p.S549S;hgvs_nt=NC_045512.2:g.1647C>T;hgvs_aa=YP_009724389.1:p.Ser549Ser;hgvs_alias=YP_009724389.1:Ser369Ser;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	2270	2270	.	+	.	ID=ID_17;Name=K669Q;alias=K489Q;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=A;Variant_seq=C;nt_name=g.A2005C;aa_name=p.K669Q;hgvs_nt=NC_045512.2:g.2005A>C;hgvs_aa=YP_009724389.1:p.Lys669Gln;hgvs_alias=YP_009724389.1:Lys489Gln;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	2503	2503	.	+	.	ID=ID_18;Name=T746T;alias=T566T;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=28;ao=9;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A2238G;aa_name=p.T746T;hgvs_nt=NC_045512.2:g.2238A>G;hgvs_aa=YP_009724389.1:p.Thr746Thr;hgvs_alias=YP_009724389.1:Thr566Thr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.24324324324324326;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	2551	2551	.	+	.	ID=ID_19;Name=D762D;alias=D582D;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T2286C;aa_name=p.D762D;hgvs_nt=NC_045512.2:g.2286T>C;hgvs_aa=YP_009724389.1:p.Asp762Asp;hgvs_alias=YP_009724389.1:Asp582Asp;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	2640	2640	.	+	.	ID=ID_20;Name=E792A;alias=E612A;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:181..818;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=A;Variant_seq=C;nt_name=g.A2375C;aa_name=p.E792A;hgvs_nt=NC_045512.2:g.2375A>C;hgvs_aa=YP_009724389.1:p.Glu792Ala;hgvs_alias=YP_009724389.1:Glu612Ala;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	2790	2790	.	+	.	ID=ID_21;Name=T842I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C2525T;aa_name=p.T842I;hgvs_nt=NC_045512.2:g.2525C>T;hgvs_aa=YP_009724389.1:p.Thr842Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	3037	3037	.	+	.	ID=ID_22;Name=F924F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C2772T;aa_name=p.F924F;hgvs_nt=NC_045512.2:g.2772C>T;hgvs_aa=YP_009724389.1:p.Phe924Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	3166	3166	.	+	.	ID=ID_23;Name=A967A;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T2901C;aa_name=p.A967A;hgvs_nt=NC_045512.2:g.2901T>C;hgvs_aa=YP_009724389.1:p.Ala967Ala;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	3335	3335	.	+	.	ID=ID_24;Name=E1024K;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=G;Variant_seq=A;nt_name=g.G3070A;aa_name=p.E1024K;hgvs_nt=NC_045512.2:g.3070G>A;hgvs_aa=YP_009724389.1:p.Glu1024Lys;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	4184	4184	.	+	.	ID=ID_25;Name=G1307S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=A;nt_name=g.G3919A;aa_name=p.G1307S;hgvs_nt=NC_045512.2:g.3919G>A;hgvs_aa=YP_009724389.1:p.Gly1307Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	4255	4255	.	+	.	ID=ID_26;Name=P1330P;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G3990T;aa_name=p.P1330P;hgvs_nt=NC_045512.2:g.3990G>T;hgvs_aa=YP_009724389.1:p.Pro1330Pro;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	4321	4321	.	+	.	ID=ID_27;Name=A1352A;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C4056T;aa_name=p.A1352A;hgvs_nt=NC_045512.2:g.4056C>T;hgvs_aa=YP_009724389.1:p.Ala1352Ala;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	4668	4668	.	+	.	ID=ID_28;Name=S1468F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C4403T;aa_name=p.S1468F;hgvs_nt=NC_045512.2:g.4403C>T;hgvs_aa=YP_009724389.1:p.Ser1468Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	4723	4723	.	+	.	ID=ID_29;Name=Y1486Y;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=28;ao=9;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T4458C;aa_name=p.Y1486Y;hgvs_nt=NC_045512.2:g.4458T>C;hgvs_aa=YP_009724389.1:p.Tyr1486Tyr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.24324324324324326;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	5321	5321	.	+	.	ID=ID_30;Name=I1686L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=A;Variant_seq=C;nt_name=g.A5056C;aa_name=p.I1686L;hgvs_nt=NC_045512.2:g.5056A>C;hgvs_aa=YP_009724389.1:p.Ile1686Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	5807	5807	.	+	.	ID=ID_31;Name=I1848V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A5542G;aa_name=p.I1848V;hgvs_nt=NC_045512.2:g.5542A>G;hgvs_aa=YP_009724389.1:p.Ile1848Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	5878	5878	.	+	.	ID=ID_32;Name=N1871N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C5613T;aa_name=p.N1871N;hgvs_nt=NC_045512.2:g.5613C>T;hgvs_aa=YP_009724389.1:p.Asn1871Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	5892	5892	.	+	.	ID=ID_33;Name=T1876I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C5627T;aa_name=p.T1876I;hgvs_nt=NC_045512.2:g.5627C>T;hgvs_aa=YP_009724389.1:p.Thr1876Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	5907	5907	.	+	.	ID=ID_34;Name=T1881I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C5642T;aa_name=p.T1881I;hgvs_nt=NC_045512.2:g.5642C>T;hgvs_aa=YP_009724389.1:p.Thr1881Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	6027	6027	.	+	.	ID=ID_35;Name=P1921L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C5762T;aa_name=p.P1921L;hgvs_nt=NC_045512.2:g.5762C>T;hgvs_aa=YP_009724389.1:p.Pro1921Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	6151	6151	.	+	.	ID=ID_36;Name=D1962E;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=A;nt_name=g.C5886A;aa_name=p.D1962E;hgvs_nt=NC_045512.2:g.5886C>A;hgvs_aa=YP_009724389.1:p.Asp1962Glu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	6604	6604	.	+	.	ID=ID_37;Name=L2113L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=28;ao=9;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A6339G;aa_name=p.L2113L;hgvs_nt=NC_045512.2:g.6339A>G;hgvs_aa=YP_009724389.1:p.Leu2113Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.24324324324324326;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	7098	7098	.	+	.	ID=ID_38;Name=I2278T;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T6833C;aa_name=p.I2278T;hgvs_nt=NC_045512.2:g.6833T>C;hgvs_aa=YP_009724389.1:p.Ile2278Thr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	7225	7225	.	+	.	ID=ID_39;Name=A2320A;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=T;Variant_seq=G;nt_name=g.T6960G;aa_name=p.A2320A;hgvs_nt=NC_045512.2:g.6960T>G;hgvs_aa=YP_009724389.1:p.Ala2320Ala;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	7581	7581	.	+	.	ID=ID_40;Name=N2439S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A7316G;aa_name=p.N2439S;hgvs_nt=NC_045512.2:g.7316A>G;hgvs_aa=YP_009724389.1:p.Asn2439Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	8278	8278	.	+	.	ID=ID_41;Name=N2671N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=PL_pro;mat_pep_desc=former nsp1%3B conserved domains are: N-terminal acidic (Ac)%2C predicted phosphoesterase%2C papain-like proteinase%2C Y-domain%2C transmembrane domain 1 (TM1)%2C adenosine diphosphate-ribose 1''-phosphatase (ADRP)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:819..2763;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T8013C;aa_name=p.N2671N;hgvs_nt=NC_045512.2:g.8013T>C;hgvs_aa=YP_009724389.1:p.Asn2671Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	9195	9195	.	+	.	ID=ID_42;Name=T2977I;alias=T214I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C8930T;aa_name=p.T2977I;hgvs_nt=NC_045512.2:g.8930C>T;hgvs_aa=YP_009724389.1:p.Thr2977Ile;hgvs_alias=YP_009724389.1:Thr214Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	9344	9344	.	+	.	ID=ID_43;Name=L3027F;alias=L264F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C9079T;aa_name=p.L3027F;hgvs_nt=NC_045512.2:g.9079C>T;hgvs_aa=YP_009724389.1:p.Leu3027Phe;hgvs_alias=YP_009724389.1:Leu264Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	9424	9424	.	+	.	ID=ID_44;Name=V3053V;alias=V290V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A9159G;aa_name=p.V3053V;hgvs_nt=NC_045512.2:g.9159A>G;hgvs_aa=YP_009724389.1:p.Val3053Val;hgvs_alias=YP_009724389.1:Val290Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	9438	9438	.	+	.	ID=ID_45;Name=T3058I;alias=T295I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C9173T;aa_name=p.T3058I;hgvs_nt=NC_045512.2:g.9173C>T;hgvs_aa=YP_009724389.1:p.Thr3058Ile;hgvs_alias=YP_009724389.1:Thr295Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	9534	9534	.	+	.	ID=ID_46;Name=T3090I;alias=T327I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C9269T;aa_name=p.T3090I;hgvs_nt=NC_045512.2:g.9269C>T;hgvs_aa=YP_009724389.1:p.Thr3090Ile;hgvs_alias=YP_009724389.1:Thr327Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	9671	9671	.	+	.	ID=ID_47;Name=V3136I;alias=V373I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=G;Variant_seq=A;nt_name=g.G9406A;aa_name=p.V3136I;hgvs_nt=NC_045512.2:g.9406G>A;hgvs_aa=YP_009724389.1:p.Val3136Ile;hgvs_alias=YP_009724389.1:Val373Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	9856	9856	.	+	.	ID=ID_48;Name=V3197V;alias=V434V;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G9591T;aa_name=p.V3197V;hgvs_nt=NC_045512.2:g.9591G>T;hgvs_aa=YP_009724389.1:p.Val3197Val;hgvs_alias=YP_009724389.1:Val434Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	9866	9866	.	+	.	ID=ID_49;Name=L3201F;alias=L438F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C9601T;aa_name=p.L3201F;hgvs_nt=NC_045512.2:g.9601C>T;hgvs_aa=YP_009724389.1:p.Leu3201Phe;hgvs_alias=YP_009724389.1:Leu438Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	10029	10029	.	+	.	ID=ID_50;Name=T3255I;alias=T492I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp4;mat_pep_desc=nsp4B_TM%3B contains transmembrane domain 2 (TM2)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:2764..3263;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C9764T;aa_name=p.T3255I;hgvs_nt=NC_045512.2:g.9764C>T;hgvs_aa=YP_009724389.1:p.Thr3255Ile;hgvs_alias=YP_009724389.1:Thr492Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	10153	10153	.	+	.	ID=ID_51;Name=D3296D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T9888C;aa_name=p.D3296D;hgvs_nt=NC_045512.2:g.9888T>C;hgvs_aa=YP_009724389.1:p.Asp3296Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	10156	10156	.	+	.	ID=ID_52;Name=D3297D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C9891T;aa_name=p.D3297D;hgvs_nt=NC_045512.2:g.9891C>T;hgvs_aa=YP_009724389.1:p.Asp3297Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	10198	10198	.	+	.	ID=ID_53;Name=D3311D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C9933T;aa_name=p.D3311D;hgvs_nt=NC_045512.2:g.9933C>T;hgvs_aa=YP_009724389.1:p.Asp3311Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	10364	10364	.	+	.	ID=ID_54;Name=V3367F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G10099T;aa_name=p.V3367F;hgvs_nt=NC_045512.2:g.10099G>T;hgvs_aa=YP_009724389.1:p.Val3367Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	10447	10447	.	+	.	ID=ID_55;Name=P3395H;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=GCC;Variant_seq=ACA;nt_name=g.GCC10182_10184ACA;aa_name=p.P3395H;hgvs_nt=n/a;hgvs_aa=YP_009724389.1:p.Pro3395His;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	10497	10497	.	+	.	ID=ID_56;Name=V3411A;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T10232C;aa_name=p.V3411A;hgvs_nt=NC_045512.2:g.10232T>C;hgvs_aa=YP_009724389.1:p.Val3411Ala;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	10833	10833	.	+	.	ID=ID_57;Name=A3523V;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=3CL;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro%3B main proteinase (Mpro)%3B mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al.%2C 2003)%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3264..3569;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C10568T;aa_name=p.A3523V;hgvs_nt=NC_045512.2:g.10568C>T;hgvs_aa=YP_009724389.1:p.Ala3523Val;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	11020	11020	.	+	.	ID=ID_58;Name=L3585L;alias=L16L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C10755T;aa_name=p.L3585L;hgvs_nt=NC_045512.2:g.10755C>T;hgvs_aa=YP_009724389.1:p.Leu3585Leu;hgvs_alias=YP_009724389.1:Leu16Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	11083	11083	.	+	.	ID=ID_59;Name=L3606F;alias=L37F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=34;ao=3;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G10818T;aa_name=p.L3606F;hgvs_nt=NC_045512.2:g.10818G>T;hgvs_aa=YP_009724389.1:p.Leu3606Phe;hgvs_alias=YP_009724389.1:Leu37Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.08108108108108109;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	11110	11110	.	+	.	ID=ID_60;Name=A3615A;alias=A46A;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=34;ao=2;dp=36;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T10845C;aa_name=p.A3615A;hgvs_nt=NC_045512.2:g.10845T>C;hgvs_aa=YP_009724389.1:p.Ala3615Ala;hgvs_alias=YP_009724389.1:Ala46Ala;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05555555555555555;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	11287	11287	.	+	.	ID=ID_61;Name=S3675del;alias=S106_F108del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=0;ao=36;dp=36;sample_size=37;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=g.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;hgvs_nt=NC_045512.2:g.11023_11031del;hgvs_aa=YP_009724389.1:p.Ser3675_Phe3677del;hgvs_alias=YP_009724389.1:Ser106_Phe108del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=S3675_F3677del;multiaa_comb_mutation=3676del,F3677del;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	11287	11287	.	+	.	ID=ID_61;Name=3676del;alias=S106_F108del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=0;ao=36;dp=36;sample_size=37;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=g.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;hgvs_nt=NC_045512.2:g.11023_11031del;hgvs_aa=YP_009724389.1:p.Ser3675_Phe3677del;hgvs_alias=YP_009724389.1:Ser106_Phe108del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=S3675_F3677del;multiaa_comb_mutation=S3675del,F3677del;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	11287	11287	.	+	.	ID=ID_61;Name=F3677del;alias=S106_F108del;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=0;ao=36;dp=36;sample_size=37;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=g.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;hgvs_nt=NC_045512.2:g.11023_11031del;hgvs_aa=YP_009724389.1:p.Ser3675_Phe3677del;hgvs_alias=YP_009724389.1:Ser106_Phe108del;vcf_gene=ORF1ab;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=S3675_F3677del;multiaa_comb_mutation=S3675del,3676del;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	11514	11514	.	+	.	ID=ID_62;Name=T3750I;alias=T181I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C11249T;aa_name=p.T3750I;hgvs_nt=NC_045512.2:g.11249C>T;hgvs_aa=YP_009724389.1:p.Thr3750Ile;hgvs_alias=YP_009724389.1:Thr181Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	11653	11653	.	+	.	ID=ID_63;Name=L3796L;alias=L227L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp6;mat_pep_desc=nsp6_TM%3B putative transmembrane domain%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3570..3859;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C11388T;aa_name=p.L3796L;hgvs_nt=NC_045512.2:g.11388C>T;hgvs_aa=YP_009724389.1:p.Leu3796Leu;hgvs_alias=YP_009724389.1:Leu227Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	11934	11934	.	+	.	ID=ID_64;Name=Q3890R;alias=Q31R;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp7;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3860..3942;ro=28;ao=9;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A11669G;aa_name=p.Q3890R;hgvs_nt=NC_045512.2:g.11669A>G;hgvs_aa=YP_009724389.1:p.Gln3890Arg;hgvs_alias=YP_009724389.1:Gln31Arg;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.24324324324324326;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	12615	12615	.	+	.	ID=ID_65;Name=D4117G;alias=D175G;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp8;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:3943..4140;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A12350G;aa_name=p.D4117G;hgvs_nt=NC_045512.2:g.12350A>G;hgvs_aa=YP_009724389.1:p.Asp4117Gly;hgvs_alias=YP_009724389.1:Asp175Gly;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	12741	12741	.	+	.	ID=ID_66;Name=T4159I;alias=T19I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4141..4253;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C12476T;aa_name=p.T4159I;hgvs_nt=NC_045512.2:g.12476C>T;hgvs_aa=YP_009724389.1:p.Thr4159Ile;hgvs_alias=YP_009724389.1:Thr19Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	12772	12772	.	+	.	ID=ID_67;Name=L4169L;alias=L29L;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4141..4253;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A12507G;aa_name=p.L4169L;hgvs_nt=NC_045512.2:g.12507A>G;hgvs_aa=YP_009724389.1:p.Leu4169Leu;hgvs_alias=YP_009724389.1:Leu29Leu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	12826	12826	.	+	.	ID=ID_68;Name=D4187D;alias=D47D;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4141..4253;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T12561C;aa_name=p.D4187D;hgvs_nt=NC_045512.2:g.12561T>C;hgvs_aa=YP_009724389.1:p.Asp4187Asp;hgvs_alias=YP_009724389.1:Asp47Asp;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	12838	12838	.	+	.	ID=ID_69;Name=L4191F;alias=L51F;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4141..4253;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=G;Variant_seq=C;nt_name=g.G12573C;aa_name=p.L4191F;hgvs_nt=NC_045512.2:g.12573G>C;hgvs_aa=YP_009724389.1:p.Leu4191Phe;hgvs_alias=YP_009724389.1:Leu51Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	12880	12880	.	+	.	ID=ID_70;Name=I4205I;alias=I65I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4141..4253;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C12615T;aa_name=p.I4205I;hgvs_nt=NC_045512.2:g.12615C>T;hgvs_aa=YP_009724389.1:p.Ile4205Ile;hgvs_alias=YP_009724389.1:Ile65Ile;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	13011	13011	.	+	.	ID=ID_71;Name=T4249I;alias=T109I;gene=ORF1ab;protein_name=ORF1ab polyprotein;protein_symbol=ORF1a;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp9;mat_pep_desc=ssRNA-binding protein%3B produced by both pp1a and pp1ab;mat_pep_acc=id-YP_009724389.1:4141..4253;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C12746T;aa_name=p.T4249I;hgvs_nt=NC_045512.2:g.12746C>T;hgvs_aa=YP_009724389.1:p.Thr4249Ile;hgvs_alias=YP_009724389.1:Thr109Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	13474	13474	.	+	.	ID=ID_72;Name=C4404R;alias=C12R;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp11;mat_pep_desc=produced by pp1a only;mat_pep_acc=id-YP_009725295.1:4393..4405;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T13210C;aa_name=p.C4404R;hgvs_nt=NC_045512.2:g.13210T>C;hgvs_aa=YP_009724389.1:p.Cys4404Arg;hgvs_alias=YP_009724389.1:Cys12Arg;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	13982	13982	.	+	.	ID=ID_73;Name=R4573L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G13718T;aa_name=p.R4573L;hgvs_nt=NC_045512.2:g.13718G>T;hgvs_aa=YP_009724389.1:p.Arg4573Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	14225	14225	.	+	.	ID=ID_74;Name=T4654I;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=34;ao=3;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C13961T;aa_name=p.T4654I;hgvs_nt=NC_045512.2:g.13961C>T;hgvs_aa=YP_009724389.1:p.Thr4654Ile;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.08108108108108109;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	14265	14265	.	+	.	ID=ID_75;Name=F4667F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C14001T;aa_name=p.F4667F;hgvs_nt=NC_045512.2:g.14001C>T;hgvs_aa=YP_009724389.1:p.Phe4667Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	14408	14408	.	+	.	ID=ID_76;Name=P4715L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C14144T;aa_name=p.P4715L;hgvs_nt=NC_045512.2:g.14144C>T;hgvs_aa=YP_009724389.1:p.Pro4715Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	14961	14961	.	+	.	ID=ID_77;Name=N4899N;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=28;ao=9;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T14697C;aa_name=p.N4899N;hgvs_nt=NC_045512.2:g.14697T>C;hgvs_aa=YP_009724389.1:p.Asn4899Asn;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.24324324324324326;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	15036	15036	.	+	.	ID=ID_78;Name=K4924K;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A14772G;aa_name=p.K4924K;hgvs_nt=NC_045512.2:g.14772A>G;hgvs_aa=YP_009724389.1:p.Lys4924Lys;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	15225	15225	.	+	.	ID=ID_79;Name=Y4987Y;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T14961C;aa_name=p.Y4987Y;hgvs_nt=NC_045512.2:g.14961T>C;hgvs_aa=YP_009724389.1:p.Tyr4987Tyr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	15437	15437	.	+	.	ID=ID_80;Name=M5058T;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=34;ao=2;dp=36;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T15173C;aa_name=p.M5058T;hgvs_nt=NC_045512.2:g.15173T>C;hgvs_aa=YP_009724389.1:p.Met5058Thr;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05555555555555555;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	15451	15451	.	+	.	ID=ID_81;Name=G5063S;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=36;dp=36;sample_size=37;Reference_seq=G;Variant_seq=A;nt_name=g.G15187A;aa_name=p.G5063S;hgvs_nt=NC_045512.2:g.15187G>A;hgvs_aa=YP_009724389.1:p.Gly5063Ser;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	15538	15538	.	+	.	ID=ID_82;Name=V5092L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=35;ao=1;dp=36;sample_size=37;Reference_seq=G;Variant_seq=C;nt_name=g.G15274C;aa_name=p.V5092L;hgvs_nt=NC_045512.2:g.15274G>C;hgvs_aa=YP_009724389.1:p.Val5092Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.027777777777777776;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	15714	15714	.	+	.	ID=ID_83;Name=L5150L;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C15450T;aa_name=p.L5150L;hgvs_nt=NC_045512.2:g.15450C>T;hgvs_aa=YP_009724389.1:p.Leu5150Leu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	15738	15738	.	+	.	ID=ID_84;Name=F5158F;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C15474T;aa_name=p.F5158F;hgvs_nt=NC_045512.2:g.15474C>T;hgvs_aa=YP_009724389.1:p.Phe5158Phe;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	15846	15846	.	+	.	ID=ID_85;Name=E5194E;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=G;Variant_seq=A;nt_name=g.G15582A;aa_name=p.E5194E;hgvs_nt=NC_045512.2:g.15582G>A;hgvs_aa=YP_009724389.1:p.Glu5194Glu;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	15939	15939	.	+	.	ID=ID_86;Name=D5225D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T15675C;aa_name=p.D5225D;hgvs_nt=NC_045512.2:g.15675T>C;hgvs_aa=YP_009724389.1:p.Asp5225Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	16119	16119	.	+	.	ID=ID_87;Name=D5285D;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T15855C;aa_name=p.D5285D;hgvs_nt=NC_045512.2:g.15855T>C;hgvs_aa=YP_009724389.1:p.Asp5285Asp;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	16221	16221	.	+	.	ID=ID_88;Name=P5319P;alias=n/a;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=G;Variant_seq=A;nt_name=g.G15957A;aa_name=p.P5319P;hgvs_nt=NC_045512.2:g.15957G>A;hgvs_aa=YP_009724389.1:p.Pro5319Pro;hgvs_alias=n/a;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	16342	16342	.	+	.	ID=ID_89;Name=S5360P;alias=S36P;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T16078C;aa_name=p.S5360P;hgvs_nt=NC_045512.2:g.16078T>C;hgvs_aa=YP_009724389.1:p.Ser5360Pro;hgvs_alias=YP_009724389.1:Ser36Pro;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	16639	16639	.	+	.	ID=ID_90;Name=A5459S;alias=A135S;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G16375T;aa_name=p.A5459S;hgvs_nt=NC_045512.2:g.16375G>T;hgvs_aa=YP_009724389.1:p.Ala5459Ser;hgvs_alias=YP_009724389.1:Ala135Ser;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	17410	17410	.	+	.	ID=ID_91;Name=R5716C;alias=R392C;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C17146T;aa_name=p.R5716C;hgvs_nt=NC_045512.2:g.17146C>T;hgvs_aa=YP_009724389.1:p.Arg5716Cys;hgvs_alias=YP_009724389.1:Arg392Cys;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	17502	17502	.	+	.	ID=ID_92;Name=F5746F;alias=F422F;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C17238T;aa_name=p.F5746F;hgvs_nt=NC_045512.2:g.17238C>T;hgvs_aa=YP_009724389.1:p.Phe5746Phe;hgvs_alias=YP_009724389.1:Phe422Phe;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	17676	17676	.	+	.	ID=ID_93;Name=I5804I;alias=I480I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C17412T;aa_name=p.I5804I;hgvs_nt=NC_045512.2:g.17412C>T;hgvs_aa=YP_009724389.1:p.Ile5804Ile;hgvs_alias=YP_009724389.1:Ile480Ile;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	17766	17766	.	+	.	ID=ID_94;Name=V5834V;alias=V510V;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C17502T;aa_name=p.V5834V;hgvs_nt=NC_045512.2:g.17502C>T;hgvs_aa=YP_009724389.1:p.Val5834Val;hgvs_alias=YP_009724389.1:Val510Val;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	17859	17859	.	+	.	ID=ID_95;Name=Y5865Y;alias=Y541Y;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp13;mat_pep_desc=nsp13_ZBD%2C nsp13_TB%2C and nsp_HEL1core%3B zinc-binding domain (ZD)%2C NTPase/helicase domain (HEL)%2C RNA 5'-triphosphatase%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5325..5925;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T17595C;aa_name=p.Y5865Y;hgvs_nt=NC_045512.2:g.17595T>C;hgvs_aa=YP_009724389.1:p.Tyr5865Tyr;hgvs_alias=YP_009724389.1:Tyr541Tyr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	18163	18163	.	+	.	ID=ID_96;Name=I5967V;alias=I42V;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A17899G;aa_name=p.I5967V;hgvs_nt=NC_045512.2:g.17899A>G;hgvs_aa=YP_009724389.1:p.Ile5967Val;hgvs_alias=YP_009724389.1:Ile42Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	18171	18171	.	+	.	ID=ID_97;Name=G5969G;alias=G44G;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C17907T;aa_name=p.G5969G;hgvs_nt=NC_045512.2:g.17907C>T;hgvs_aa=YP_009724389.1:p.Gly5969Gly;hgvs_alias=YP_009724389.1:Gly44Gly;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	18417	18417	.	+	.	ID=ID_98;Name=D6051D;alias=D126D;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T18153C;aa_name=p.D6051D;hgvs_nt=NC_045512.2:g.18153T>C;hgvs_aa=YP_009724389.1:p.Asp6051Asp;hgvs_alias=YP_009724389.1:Asp126Asp;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	18453	18453	.	+	.	ID=ID_99;Name=A6063A;alias=A138A;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T18189C;aa_name=p.A6063A;hgvs_nt=NC_045512.2:g.18189T>C;hgvs_aa=YP_009724389.1:p.Ala6063Ala;hgvs_alias=YP_009724389.1:Ala138Ala;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	18471	18471	.	+	.	ID=ID_100;Name=D6069D;alias=D144D;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T18207C;aa_name=p.D6069D;hgvs_nt=NC_045512.2:g.18207T>C;hgvs_aa=YP_009724389.1:p.Asp6069Asp;hgvs_alias=YP_009724389.1:Asp144Asp;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	18508	18508	.	+	.	ID=ID_101;Name=L6082F;alias=L157F;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C18244T;aa_name=p.L6082F;hgvs_nt=NC_045512.2:g.18244C>T;hgvs_aa=YP_009724389.1:p.Leu6082Phe;hgvs_alias=YP_009724389.1:Leu157Phe;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	18711	18711	.	+	.	ID=ID_102;Name=Y6149Y;alias=Y224Y;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T18447C;aa_name=p.Y6149Y;hgvs_nt=NC_045512.2:g.18447T>C;hgvs_aa=YP_009724389.1:p.Tyr6149Tyr;hgvs_alias=YP_009724389.1:Tyr224Tyr;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	18981	18981	.	+	.	ID=ID_103;Name=H6239H;alias=H314H;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C18717T;aa_name=p.H6239H;hgvs_nt=NC_045512.2:g.18717C>T;hgvs_aa=YP_009724389.1:p.His6239His;hgvs_alias=YP_009724389.1:His314His;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	19017	19017	.	+	.	ID=ID_104;Name=F6251F;alias=F326F;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C18753T;aa_name=p.F6251F;hgvs_nt=NC_045512.2:g.18753C>T;hgvs_aa=YP_009724389.1:p.Phe6251Phe;hgvs_alias=YP_009724389.1:Phe326Phe;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	19038	19038	.	+	.	ID=ID_105;Name=G6258G;alias=G333G;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T18774C;aa_name=p.G6258G;hgvs_nt=NC_045512.2:g.18774T>C;hgvs_aa=YP_009724389.1:p.Gly6258Gly;hgvs_alias=YP_009724389.1:Gly333Gly;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	19326	19326	.	+	.	ID=ID_106;Name=P6354P;alias=P429P;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A19062G;aa_name=p.P6354P;hgvs_nt=NC_045512.2:g.19062A>G;hgvs_aa=YP_009724389.1:p.Pro6354Pro;hgvs_alias=YP_009724389.1:Pro429Pro;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	19388	19388	.	+	.	ID=ID_107;Name=S6375N;alias=S450N;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp14;mat_pep_desc=nsp14A2_ExoN and nsp14B_NMT%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:5926..6452;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=G;Variant_seq=A;nt_name=g.G19124A;aa_name=p.S6375N;hgvs_nt=NC_045512.2:g.19124G>A;hgvs_aa=YP_009724389.1:p.Ser6375Asn;hgvs_alias=YP_009724389.1:Ser450Asn;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	19737	19737	.	+	.	ID=ID_108;Name=D6491E;alias=D39E;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=G;nt_name=g.T19473G;aa_name=p.D6491E;hgvs_nt=NC_045512.2:g.19473T>G;hgvs_aa=YP_009724389.1:p.Asp6491Glu;hgvs_alias=YP_009724389.1:Asp39Glu;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	19955	19955	.	+	.	ID=ID_109;Name=T6564I;alias=T112I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C19691T;aa_name=p.T6564I;hgvs_nt=NC_045512.2:g.19691C>T;hgvs_aa=YP_009724389.1:p.Thr6564Ile;hgvs_alias=YP_009724389.1:Thr112Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	20016	20016	.	+	.	ID=ID_110;Name=D6584D;alias=D132D;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C19752T;aa_name=p.D6584D;hgvs_nt=NC_045512.2:g.19752C>T;hgvs_aa=YP_009724389.1:p.Asp6584Asp;hgvs_alias=YP_009724389.1:Asp132Asp;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	20055	20055	.	+	.	ID=ID_111;Name=E6597E;alias=E145E;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A19791G;aa_name=p.E6597E;hgvs_nt=NC_045512.2:g.19791A>G;hgvs_aa=YP_009724389.1:p.Glu6597Glu;hgvs_alias=YP_009724389.1:Glu145Glu;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	20173	20173	.	+	.	ID=ID_112;Name=V6637I;alias=V185I;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=2;ao=35;dp=37;sample_size=37;Reference_seq=G;Variant_seq=A;nt_name=g.G19909A;aa_name=p.V6637I;hgvs_nt=NC_045512.2:g.19909G>A;hgvs_aa=YP_009724389.1:p.Val6637Ile;hgvs_alias=YP_009724389.1:Val185Ile;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9459459459459459;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	20431	20431	.	+	.	ID=ID_113;Name=M6723V;alias=M271V;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A20167G;aa_name=p.M6723V;hgvs_nt=NC_045512.2:g.20167A>G;hgvs_aa=YP_009724389.1:p.Met6723Val;hgvs_alias=YP_009724389.1:Met271Val;vcf_gene=ORF1ab;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	20565	20565	.	+	.	ID=ID_114;Name=S6767S;alias=S315S;gene=ORF1ab;protein_name=ORF1ab polyprotein-i;protein_symbol=ORF1b;protein_id=YP_009724389.1;ps_filter=n/a;ps_exc=n/a;mat_pep=nsp15;mat_pep_desc=nsp15-A1 and nsp15B-NendoU%3B produced by pp1ab only;mat_pep_acc=id-YP_009724389.1:6453..6798;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=A;nt_name=g.T20301A;aa_name=p.S6767S;hgvs_nt=NC_045512.2:g.20301T>A;hgvs_aa=YP_009724389.1:p.Ser6767Ser;hgvs_alias=YP_009724389.1:Ser315Ser;vcf_gene=ORF1ab;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	21614	21614	.	+	.	ID=ID_115;Name=T19I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1;dp=37;sample_size=37;Reference_seq=CTTACAA;Variant_seq=TTTATAA;nt_name=g.C56T;aa_name=p.T19I;hgvs_nt=NC_045512.2:g.56C>T;hgvs_aa=YP_009724390.1:p.Thr19Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	21614	21614	.	+	.	ID=ID_116;Name=LT18FI;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1;dp=37;sample_size=37;Reference_seq=CTTACAA;Variant_seq=CTTATAG;nt_name=g.CTTAC52_56TTTAT;aa_name=p.LT18FI;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.LeuThr18PheIle;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	21614	21614	.	+	.	ID=ID_117;Name=TT19IA;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=35;dp=37;sample_size=37;Reference_seq=CTTACAA;Variant_seq=CTTATAA;nt_name=g.CAA56_58TAG;aa_name=p.TT19IA;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.ThrThr19IleAla;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9459459459459459;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	21632	21632	.	+	.	ID=ID_118;Name=L24_A27delinsS;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=TTACCCCCTG;Variant_seq=T;nt_name=g.71_79delTACCCCCTG;aa_name=p.L24_A27delinsS;hgvs_nt=NC_045512.2:g.71_79del;hgvs_aa=YP_009724390.1:p.Leu24_Ala27delinsSer;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	21658	21658	.	+	.	ID=ID_119;Name=F32F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C96T;aa_name=p.F32F;hgvs_nt=NC_045512.2:g.96C>T;hgvs_aa=YP_009724390.1:p.Phe32Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	21668	21668	.	+	.	ID=ID_120;Name=V36I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=G;Variant_seq=A;nt_name=g.G106A;aa_name=p.V36I;hgvs_nt=NC_045512.2:g.106G>A;hgvs_aa=YP_009724390.1:p.Val36Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	21810	21810	.	+	.	ID=ID_121;Name=V83A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T248C;aa_name=p.V83A;hgvs_nt=NC_045512.2:g.248T>C;hgvs_aa=YP_009724390.1:p.Val83Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	21987	21987	.	+	.	ID=ID_122;Name=G142_Y144delinsDV;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=GTGTTTA;Variant_seq=ATGT;nt_name=g.GTGTTTA425_431ATGT;aa_name=p.G142_Y144delinsDV;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Gly142_Tyr144delinsAspVal;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	21998	21998	.	+	.	ID=ID_123;Name=H146Q;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=6;dp=37;sample_size=37;Reference_seq=CAC;Variant_seq=AAA;nt_name=g.C438A;aa_name=p.H146Q;hgvs_nt=NC_045512.2:g.438C>A;hgvs_aa=YP_009724390.1:p.His146Gln;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.16216216216216217;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	21998	21998	.	+	.	ID=ID_124;Name=H146K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=31;dp=37;sample_size=37;Reference_seq=CAC;Variant_seq=CAA;nt_name=g.CAC436_438AAA;aa_name=p.H146K;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.His146Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.8378378378378378;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22104	22104	.	+	.	ID=ID_125;Name=G181V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G542T;aa_name=p.G181V;hgvs_nt=NC_045512.2:g.542G>T;hgvs_aa=YP_009724390.1:p.Gly181Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22109	22109	.	+	.	ID=ID_126;Name=Q183E;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=2;dp=37;sample_size=37;Reference_seq=CAGGG;Variant_seq=GAGGA;nt_name=g.C547G;aa_name=p.Q183E;hgvs_nt=NC_045512.2:g.547C>G;hgvs_aa=YP_009724390.1:p.Gln183Glu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22109	22109	.	+	.	ID=ID_127;Name=QG183ED;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1;dp=37;sample_size=37;Reference_seq=CAGGG;Variant_seq=GAGGT;nt_name=g.CAGGG547_551GAGGA;aa_name=p.QG183ED;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.GlnGly183GluAsp;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22109	22109	.	+	.	ID=ID_128;Name=QG183EV;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=34;dp=37;sample_size=37;Reference_seq=CAGGG;Variant_seq=GAGGG;nt_name=g.CAGGG547_551GAGGT;aa_name=p.QG183EV;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.GlnGly183GluVal;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.918918918918919;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22200	22200	.	+	.	ID=ID_129;Name=V213E;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=A;nt_name=g.T638A;aa_name=p.V213E;hgvs_nt=NC_045512.2:g.638T>A;hgvs_aa=YP_009724390.1:p.Val213Glu;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22205	22205	.	+	.	ID=ID_130;Name=D215H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=C;nt_name=g.G643C;aa_name=p.D215H;hgvs_nt=NC_045512.2:g.643G>C;hgvs_aa=YP_009724390.1:p.Asp215His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22228	22228	.	+	.	ID=ID_131;Name=A222A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=G;nt_name=g.T666G;aa_name=p.A222A;hgvs_nt=NC_045512.2:g.666T>G;hgvs_aa=YP_009724390.1:p.Ala222Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22317	22317	.	+	.	ID=ID_132;Name=G252V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=1;ao=23;dp=24;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G755T;aa_name=p.G252V;hgvs_nt=NC_045512.2:g.755G>T;hgvs_aa=YP_009724390.1:p.Gly252Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9583333333333334;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22577	22577	.	+	.	ID=ID_133;Name=G339H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=GG;Variant_seq=CA;nt_name=g.GG1015_1016CA;aa_name=p.G339H;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Gly339His;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.15 fold;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22599	22599	.	+	.	ID=ID_134;Name=R346T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=C;nt_name=g.G1037C;aa_name=p.R346T;hgvs_nt=NC_045512.2:g.1037G>C;hgvs_aa=YP_009724390.1:p.Arg346Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.06 fold;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22599	22599	.	+	.	ID=ID_134;Name=R346T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=C;nt_name=g.G1037C;aa_name=p.R346T;hgvs_nt=NC_045512.2:g.1037G>C;hgvs_aa=YP_009724390.1:p.Arg346Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41586-022-05644-7;citation=Cao et al. (2022);comb_mutation=;function_description=Increase immune evasion.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22599	22599	.	+	.	ID=ID_134;Name=R346T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=C;nt_name=g.G1037C;aa_name=p.R346T;hgvs_nt=NC_045512.2:g.1037G>C;hgvs_aa=YP_009724390.1:p.Arg346Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.15 fold;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22604	22604	.	+	.	ID=ID_135;Name=A348T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=G;Variant_seq=A;nt_name=g.G1042A;aa_name=p.A348T;hgvs_nt=NC_045512.2:g.1042G>A;hgvs_aa=YP_009724390.1:p.Ala348Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22664	22664	.	+	.	ID=ID_136;Name=L368I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=A;nt_name=g.C1102A;aa_name=p.L368I;hgvs_nt=NC_045512.2:g.1102C>A;hgvs_aa=YP_009724390.1:p.Leu368Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22674	22674	.	+	.	ID=ID_137;Name=S371F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C1112T;aa_name=p.S371F;hgvs_nt=NC_045512.2:g.1112C>T;hgvs_aa=YP_009724390.1:p.Ser371Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22679	22679	.	+	.	ID=ID_138;Name=S373P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T1117C;aa_name=p.S373P;hgvs_nt=NC_045512.2:g.1117T>C;hgvs_aa=YP_009724390.1:p.Ser373Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1128/mBio.02707-20;citation=Long et al. (2020);comb_mutation=;function_description=Reduce affinity for mildly cross-reactive CR3022 (2003 pandemic SARS monoclonal antibody cross-reactive to SARS-CoV-2);heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22686	22686	.	+	.	ID=ID_139;Name=ST375FA;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=CCA;Variant_seq=TCG;nt_name=g.CCA1124_1126TCG;aa_name=p.ST375FA;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.SerThr375PheAla;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22775	22775	.	+	.	ID=ID_140;Name=D405N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=A;nt_name=g.G1213A;aa_name=p.D405N;hgvs_nt=NC_045512.2:g.1213G>A;hgvs_aa=YP_009724390.1:p.Asp405Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22786	22786	.	+	.	ID=ID_141;Name=R408S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=C;nt_name=g.A1224C;aa_name=p.R408S;hgvs_nt=NC_045512.2:g.1224A>C;hgvs_aa=YP_009724390.1:p.Arg408Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.21 fold;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_142;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=>20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against IgG1 monoclonal antibody ab1.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_142;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs);heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_142;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Pseudotyped virus model ablates binding by RBD-directed mAbs CB6 and 910-30 (targeting the inner side of the RBD). Pseudotyped virus model impairs binding by RBD-directed mAbs 4-20 and REGN10933.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_143;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_142;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=;function_description=The K417N mutation decreased the affinity ~4 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_142;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_142;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_142;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=;function_description=The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_142;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=Laffeber et al. (2021);comb_mutation=;function_description=RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_142;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_142;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_142;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported 3-fold decrease in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_143;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_144;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,D614G;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_142;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_142;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_142;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_142;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=COR-101 lost ~6x binding against this isolated mutation. Estesevimab lost ~100x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_145;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=N501Y;function_description=COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_142;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=;function_description=In 19 convalescent human sera ~1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistence P;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	"ID=ID_142;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_142;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	"ID=ID_142;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_143;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_143;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_144;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y,D614G;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_142;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_142;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C682, and to a lesser extent C614 and C660;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_142;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.1 fold;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_142;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.86 kcal/mol (i.e. destabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22813	22813	.	+	.	ID=ID_143;Name=K417N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G1251T;aa_name=p.K417N;hgvs_nt=NC_045512.2:g.1251G>T;hgvs_aa=YP_009724390.1:p.Lys417Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22882	22882	.	+	.	ID=ID_146;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2;citation=Gaebler et al. (2021);comb_mutation=;function_description=Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22882	22882	.	+	.	ID=ID_146;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22882	22882	.	+	.	ID=ID_146;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://science.sciencemag.org/content/371/6531/823;citation=Rappazzo et al. (2021);comb_mutation=;function_description=Greater than 10-fold reduction of binding effeiency vs wild type for mAb LY-CoV555. Abolishes binding of mAb ADG-1.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22882	22882	.	+	.	ID=ID_146;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://virologyj.biomedcentral.com/articles/10.1186/s12985-021-01554-8;citation=Cheng et al. (2021);comb_mutation=;function_description=N501Y substitution decreased the neutralizing and binding activities of CB6 and increased that of BD-23;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22882	22882	.	+	.	ID=ID_146;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.07 fold;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22882	22882	.	+	.	ID=ID_146;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.biorxiv.org/content/10.1101/2021.04.30.441434v1;citation=Tandel et al. (2021);comb_mutation=;function_description=The N440K variant produced ten times higher infectious viral titers than a prevalent A2a strain,  and over 1000 folds higher titers than a much less prevalent A3i strain prototype in Caco2 cells.  Interestingly, A3i strain showed the highest viral RNA levels, but the lowest infectious titers  in the culture supernatants, indicating the absence of correlation between the RNA content and the infectivity of the sample.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22882	22882	.	+	.	ID=ID_146;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Class 3 antibody C669 mildly selected for the emergence of the N440K mutation in vitro (in contrast to N440H which caused mild escape in Class 1/2 mAb C653).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22882	22882	.	+	.	ID=ID_146;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf;citation=Weisblum et al. (2020);comb_mutation=;function_description=Positive selection (up to 45% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, eliminated in subsequent passages;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22882	22882	.	+	.	ID=ID_147;Name=N440K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=G;nt_name=g.T1320G;aa_name=p.N440K;hgvs_nt=NC_045512.2:g.1320T>G;hgvs_aa=YP_009724390.1:p.Asn440Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1002/jmv.26997;citation=Rani et al. (2021);comb_mutation=D614G;function_description=A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22895	22895	.	+	.	ID=ID_148;Name=VG445PS;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=GTTG;Variant_seq=CCTA;nt_name=g.GTTG1333_1336CCTA;aa_name=p.VG445PS;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.ValGly445ProSer;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22942	22942	.	+	.	ID=ID_149;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1;dp=37;sample_size=37;Reference_seq=TCTC;Variant_seq=GCTT;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22942	22942	.	+	.	ID=ID_149;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1;dp=37;sample_size=37;Reference_seq=TCTC;Variant_seq=GCTT;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.09 fold;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22942	22942	.	+	.	ID=ID_149;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1;dp=37;sample_size=37;Reference_seq=TCTC;Variant_seq=GCTT;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22942	22942	.	+	.	ID=ID_149;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1;dp=37;sample_size=37;Reference_seq=TCTC;Variant_seq=GCTT;nt_name=g.T1380G;aa_name=p.N460K;hgvs_nt=NC_045512.2:g.1380T>G;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22942	22942	.	+	.	ID=ID_149;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=36;dp=37;sample_size=37;Reference_seq=TCTC;Variant_seq=GCTC;nt_name=g.TCTC1380_1383GCTT;aa_name=p.N460K;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.972972972972973;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=;function_description=Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22942	22942	.	+	.	ID=ID_149;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=36;dp=37;sample_size=37;Reference_seq=TCTC;Variant_seq=GCTC;nt_name=g.TCTC1380_1383GCTT;aa_name=p.N460K;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.972972972972973;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.09 fold;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22942	22942	.	+	.	ID=ID_149;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=36;dp=37;sample_size=37;Reference_seq=TCTC;Variant_seq=GCTC;nt_name=g.TCTC1380_1383GCTT;aa_name=p.N460K;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.972972972972973;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22942	22942	.	+	.	ID=ID_149;Name=N460K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=36;dp=37;sample_size=37;Reference_seq=TCTC;Variant_seq=GCTC;nt_name=g.TCTC1380_1383GCTT;aa_name=p.N460K;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Asn460Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.972972972972973;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	22951	22951	.	+	.	ID=ID_150;Name=P463P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T1389C;aa_name=p.P463P;hgvs_nt=NC_045512.2:g.1389T>C;hgvs_aa=YP_009724390.1:p.Pro463Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22992	22992	.	+	.	ID=ID_151;Name=ST477NK;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=28;dp=37;sample_size=37;Reference_seq=GCAC;Variant_seq=ACAA;nt_name=g.GCAC1430_1433ACAA;aa_name=p.ST477NK;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.SerThr477AsnLys;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.7567567567567568;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	22992	22992	.	+	.	ID=ID_152;Name=ST477NR;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=9;dp=37;sample_size=37;Reference_seq=GCAC;Variant_seq=ACAG;nt_name=g.GCAC1430_1433ACAG;aa_name=p.ST477NR;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.SerThr477AsnArg;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.24324324324324326;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23013	23013	.	+	.	ID=ID_153;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2020);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23013	23013	.	+	.	ID=ID_153;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) lost ~8x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23013	23013	.	+	.	ID=ID_153;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested. Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23013	23013	.	+	.	"ID=ID_153;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1101/2020.11.30.405472;citation=Starr et al. (2020);comb_mutation=;function_description=""E484A rose in frequency in linkage with F486I, but since E484A is not an escape mutation in our maps it is not shown in other panels"";heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	snp	23013	23013	.	+	.	ID=ID_153;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23013	23013	.	+	.	ID=ID_153;Name=E484A;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=C;nt_name=g.A1451C;aa_name=p.E484A;hgvs_nt=NC_045512.2:g.1451A>C;hgvs_aa=YP_009724390.1:p.Glu484Ala;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	23018	23018	.	+	.	ID=ID_154;Name=F486P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=TT;Variant_seq=CC;nt_name=g.TT1456_1457CC;aa_name=p.F486P;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Phe486Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Ranked modestly effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	23018	23018	.	+	.	ID=ID_154;Name=F486P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=TT;Variant_seq=CC;nt_name=g.TT1456_1457CC;aa_name=p.F486P;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Phe486Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	23018	23018	.	+	.	ID=ID_154;Name=F486P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=TT;Variant_seq=CC;nt_name=g.TT1456_1457CC;aa_name=p.F486P;hgvs_nt=n/a;hgvs_aa=YP_009724390.1:p.Phe486Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.22 fold;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23031	23031	.	+	.	ID=ID_155;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=Complete loss of binding in ELISA by the variant against monoclonal antibody ab8;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23031	23031	.	+	.	ID=ID_155;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2020);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb SARS2-32.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23031	23031	.	+	.	ID=ID_155;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=;function_description=Among the first selected minor variants in an in vitro evolution experiment for ACE2 binding.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23031	23031	.	+	.	ID=ID_155;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://science.sciencemag.org/content/371/6531/823;citation=Rappazzo et al. (2021);comb_mutation=;function_description=Greater than 10-fold rediuction of binding effeiency vs wild type for mAb LY-CoV555.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23031	23031	.	+	.	ID=ID_155;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Strong reduction in neutralization capability of all 4 convalescent sera tested (3 ablations).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23031	23031	.	+	.	ID=ID_155;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23031	23031	.	+	.	ID=ID_155;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23031	23031	.	+	.	ID=ID_155;Name=F490S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T1469C;aa_name=p.F490S;hgvs_nt=NC_045512.2:g.1469T>C;hgvs_aa=YP_009724390.1:p.Phe490Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Class 2/3 mAb C603 modestly selected for the emergence of this mutation in vitro.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23042	23042	.	+	.	ID=ID_156;Name=S494P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T1480C;aa_name=p.S494P;hgvs_nt=NC_045512.2:g.1480T>C;hgvs_aa=YP_009724390.1:p.Ser494Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=immunosuppression variant emergence;source=https://www.nejm.org/doi/full/10.1056/NEJMc2031364;citation=Choi et al. (2020);comb_mutation=;function_description=Combination of RBD mutations appeared (day 75) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome complicated by diffuse alveolar hemorrhage, who was receiving anticoagulation therapy, glucocorticoids, cyclophosphamide, and intermittent rituximab and eculizumab.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23042	23042	.	+	.	ID=ID_156;Name=S494P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T1480C;aa_name=p.S494P;hgvs_nt=NC_045512.2:g.1480T>C;hgvs_aa=YP_009724390.1:p.Ser494Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2020);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb SARS2-01.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23042	23042	.	+	.	ID=ID_156;Name=S494P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T1480C;aa_name=p.S494P;hgvs_nt=NC_045512.2:g.1480T>C;hgvs_aa=YP_009724390.1:p.Ser494Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=antibody epitope effects;source=https://science.sciencemag.org/content/371/6531/823;citation=Rappazzo et al. (2021);comb_mutation=;function_description=Greater than 10-fold rediuction of binding effeiency vs wild type for mAb LY-CoV555.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23042	23042	.	+	.	ID=ID_156;Name=S494P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T1480C;aa_name=p.S494P;hgvs_nt=NC_045512.2:g.1480T>C;hgvs_aa=YP_009724390.1:p.Ser494Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.bbrc.2021.01.035;citation=Chakraborty (2021);comb_mutation=;function_description=Using molecular dynamic simulation, the mildly (~1kcal/mol) enhanced binding energy of this variant is primarily  contributed by Tyr505 (4.98 kcal/mol) which is now involved in a strong hydrogen bonding network with Arg393.  Another important energetic contribution comes from the altered orientation of Tyr41 which is now involved with  two hydrogen-bonding interactions with Asp355 and Thr500.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23042	23042	.	+	.	ID=ID_156;Name=S494P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T1480C;aa_name=p.S494P;hgvs_nt=NC_045512.2:g.1480T>C;hgvs_aa=YP_009724390.1:p.Ser494Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=;function_description=Minor variant selected in late rounds of an in vitro evolution experiment for ACE2 binding. Shown to increase the thermostability but decrease the association rate constant of the RBD to ACE2;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23042	23042	.	+	.	ID=ID_156;Name=S494P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T1480C;aa_name=p.S494P;hgvs_nt=NC_045512.2:g.1480T>C;hgvs_aa=YP_009724390.1:p.Ser494Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) lost ~8x binding against this isolated mutation. Regdanvimab lost ~32x binding against this isolated mutation.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23042	23042	.	+	.	ID=ID_156;Name=S494P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T1480C;aa_name=p.S494P;hgvs_nt=NC_045512.2:g.1480T>C;hgvs_aa=YP_009724390.1:p.Ser494Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=convalescent plasma escape;source=http://biorxiv.org/cgi/content/short/2021.04.22.441007;citation=Alenquer et al. (2021);comb_mutation=;function_description=S494P frequently engages in interactions with antibodies but not with ACE2. It reduces antibody  neutralization of all 16 convalescent sera tested, averaging WT ratio of 0.41+-0.08 (less dramatic than E484K).  This amino acid emerges as an additional hotspot for immune evasion and a target for therapies, vaccines and diagnostics. It has emerged independently in multiple lineages.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23042	23042	.	+	.	ID=ID_156;Name=S494P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T1480C;aa_name=p.S494P;hgvs_nt=NC_045512.2:g.1480T>C;hgvs_aa=YP_009724390.1:p.Ser494Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=convalescent plasma escape;source=https://doi.org/10.1016/j.chom.2021.02.003;citation=Greaney et al. (2021);comb_mutation=;function_description=In 2 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD,  S484P shows a slightly resistent profile across both timepoints (i.e. resistant to immune cell somatic mutation evolution);heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23042	23042	.	+	.	ID=ID_156;Name=S494P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T1480C;aa_name=p.S494P;hgvs_nt=NC_045512.2:g.1480T>C;hgvs_aa=YP_009724390.1:p.Ser494Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Mixed bag of positive and negative changes in neutralization capability of all 4 convalescent sera tested.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23042	23042	.	+	.	ID=ID_156;Name=S494P;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T1480C;aa_name=p.S494P;hgvs_nt=NC_045512.2:g.1480T>C;hgvs_aa=YP_009724390.1:p.Ser494Pro;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://www.nejm.org/doi/full/10.1056/NEJMc2031364;citation=Choi et al. (2020);comb_mutation=;function_description=Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://science.sciencemag.org/content/early/2021/04/29/science.abh1282;citation=Reynolds et al. (2021);comb_mutation=;function_description=Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p ;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://www.mdpi.com/2076-0817/10/2/184/htm;citation=Flores-Alanis et al. (2021);comb_mutation=;function_description=Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.04.26.441517;citation=Klegerman et al. (2021);comb_mutation=;function_description=Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=Haynes et al. (2021);comb_mutation=;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation=;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x);heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1;citation=Rees-Spear et al. (2021);comb_mutation=;function_description=Lowered the neutralization potency of mAb COVA1-12 to the limit of the assay. Decrease in potency was observed against the N501Y pseudotype for the cluster IX mAb COVA2-17.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_158;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=;function_description=The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	"ID=ID_158;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=~4-fold increase in binding affinity vs wild type.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2020.12.29.424708v1;citation=Santos and Passos (2021);comb_mutation=;function_description=In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=;function_description=The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=Laffeber et al. (2021);comb_mutation=;function_description=RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd ;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.02.428884v1;citation=Liu et al. (2021);comb_mutation=;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd ;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd ;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.11.426269v2;citation=Zhu et al. (2021);comb_mutation=;function_description=N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.09.439154v1;citation=Gamez et al. (2021);comb_mutation=;function_description=The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_158;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_158;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=D614G;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_158;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_144;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N,D614G;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_158;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully];heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_145;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=K417N;function_description=COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=;function_description=0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=;function_description=As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation=;function_description=Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1101%2F2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=;function_description=In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	"ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	"ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_158;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.02.02.21250799v1;citation=Edara et al. (2021);comb_mutation=;function_description=1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 g (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_158;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=D614G;function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_144;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N,D614G;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation=;function_description=Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1101%2F2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=;function_description=Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2;citation=Jacobson et al. (2021);comb_mutation=;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=environmental condition stability;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_157;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23063	23063	.	+	.	ID=ID_158;Name=N501Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A1501T;aa_name=p.N501Y;hgvs_nt=NC_045512.2:g.1501A>T;hgvs_aa=YP_009724390.1:p.Asn501Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23075	23075	.	+	.	ID=ID_159;Name=Y505H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T1513C;aa_name=p.Y505H;hgvs_nt=NC_045512.2:g.1513T>C;hgvs_aa=YP_009724390.1:p.Tyr505His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://dx.doi.org/10.1128/mBio.02220-20;citation=McAloose et al. (2020);comb_mutation=;function_description=Observed first in a single tiger (cohort of 5), potential adaptation.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23075	23075	.	+	.	ID=ID_159;Name=Y505H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T1513C;aa_name=p.Y505H;hgvs_nt=NC_045512.2:g.1513T>C;hgvs_aa=YP_009724390.1:p.Tyr505His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.16 fold;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23222	23222	.	+	.	ID=ID_160;Name=E554K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=G;Variant_seq=A;nt_name=g.G1660A;aa_name=p.E554K;hgvs_nt=NC_045512.2:g.1660G>A;hgvs_aa=YP_009724390.1:p.Glu554Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23248	23248	.	+	.	ID=ID_161;Name=F562F;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C1686T;aa_name=p.F562F;hgvs_nt=NC_045512.2:g.1686C>T;hgvs_aa=YP_009724390.1:p.Phe562Phe;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1;citation=Landis et al. (2021);comb_mutation=;function_description=Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_158;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_158;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_163;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=P681H;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_143;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=K417N;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_164;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=;function_description=In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_158;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_158;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=N501Y;function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_158;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_143;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N;function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_144;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N,N501Y;function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_158;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1;citation=Barrett et al. (2021);comb_mutation=;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et l. (2020);comb_mutation=;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.7554/elife.65365;citation=Daniloski et al. (2021);comb_mutation=;function_description=The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation=;function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oralnasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.nature.com/articles/s41586-020-2895-3;citation=Plante et al. (2020);comb_mutation=;function_description=Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_158;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_163;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=P681H;function_description=1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_143;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=K417N;function_description=2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_164;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_158;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=N501Y;function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_143;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N;function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_144;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=K417N,N501Y;function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n ;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=;function_description=Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (911 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccinationmean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_163;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1;citation=Zuckerman et al. (2021);comb_mutation=P681H;function_description=No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation];heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=;function_description=Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/;citation=Yurkovetskiy et al. (2020);comb_mutation=;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	snp	23403	23403	.	+	.	"ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2;citation=Weissman et al. (2020);comb_mutation=;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;"
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_162;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_147;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.1002/jmv.26997;citation=Rani et al. (2021);comb_mutation=N440K;function_description=A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_158;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=N501Y;function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_163;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=P681H;function_description=1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_143;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=K417N;function_description=1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23403	23403	.	+	.	ID=ID_164;Name=D614G;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1841G;aa_name=p.D614G;hgvs_nt=NC_045512.2:g.1841A>G;hgvs_aa=YP_009724390.1:p.Asp614Gly;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=H655Y;function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_165;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1;citation=Borges et al. (2021);comb_mutation=;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears convergent.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_164;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_165;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=anthropozoonotic events;source=https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1;citation=Esclera et al. (2021);comb_mutation=;function_description=Six minks were intranasally infected with WA1 isolate, all developed this mutation during infection.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_164;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_165;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 0.87 kcal/mol (i.e. stabilizing relative to wild type);heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23525	23525	.	+	.	ID=ID_164;Name=H655Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C1963T;aa_name=p.H655Y;hgvs_nt=NC_045512.2:g.1963C>T;hgvs_aa=YP_009724390.1:p.His655Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23599	23599	.	+	.	ID=ID_166;Name=N679K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=G;nt_name=g.T2037G;aa_name=p.N679K;hgvs_nt=NC_045512.2:g.2037T>G;hgvs_aa=YP_009724390.1:p.Asn679Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_167;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=Haynes et al. (2021);comb_mutation=;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_167;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457603/;citation=Johnson et al. (2020);comb_mutation=;function_description=This variant is adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_167;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_163;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_167;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing NO statistically significant infection rate change amongst the cells, suggesting that furin cleavage typically used for cell entry is not affected by this change one  amino acid upstream of the RXXR recognition pattern.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_167;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication;citation=Maaroufi (2021);comb_mutation=;function_description=This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_167;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.04.06.438731v1;citation=Lubinski et al. (2021);comb_mutation=;function_description=While the introduction of P681H in the SARS-CoV-2 B.1.1.7 variant may increase spike cleavage by furin-like proteases,  this does not significantly impact viral entry or cell-cell spread. We consider that other factors are at play to account  for the increased in transmission and disease severity attributed to this variant of concern (VOC).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_163;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_163;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1;citation=Zuckerman et al. (2021);comb_mutation=D614G;function_description=No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation];heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_167;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23604	23604	.	+	.	ID=ID_163;Name=P681H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=A;nt_name=g.C2042A;aa_name=p.P681H;hgvs_nt=NC_045512.2:g.2042C>A;hgvs_aa=YP_009724390.1:p.Pro681His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation=D614G;function_description=1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23613	23613	.	+	.	ID=ID_168;Name=A684V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C2051T;aa_name=p.A684V;hgvs_nt=NC_045512.2:g.2051C>T;hgvs_aa=YP_009724390.1:p.Ala684Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23780	23780	.	+	.	ID=ID_169;Name=M740V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A2218G;aa_name=p.M740V;hgvs_nt=NC_045512.2:g.2218A>G;hgvs_aa=YP_009724390.1:p.Met740Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23849	23849	.	+	.	ID=ID_170;Name=L763L;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T2287C;aa_name=p.L763L;hgvs_nt=NC_045512.2:g.2287T>C;hgvs_aa=YP_009724390.1:p.Leu763Leu;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	23854	23854	.	+	.	ID=ID_171;Name=N764K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=A;nt_name=g.C2292A;aa_name=p.N764K;hgvs_nt=NC_045512.2:g.2292C>A;hgvs_aa=YP_009724390.1:p.Asn764Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	24116	24116	.	+	.	ID=ID_172;Name=A852T;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=28;ao=9;dp=37;sample_size=37;Reference_seq=G;Variant_seq=A;nt_name=g.G2554A;aa_name=p.A852T;hgvs_nt=NC_045512.2:g.2554G>A;hgvs_aa=YP_009724390.1:p.Ala852Thr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.24324324324324326;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	24331	24331	.	+	.	ID=ID_173;Name=I923I;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T2769C;aa_name=p.I923I;hgvs_nt=NC_045512.2:g.2769T>C;hgvs_aa=YP_009724390.1:p.Ile923Ile;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	24337	24337	.	+	.	ID=ID_174;Name=N925N;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C2775T;aa_name=p.N925N;hgvs_nt=NC_045512.2:g.2775C>T;hgvs_aa=YP_009724390.1:p.Asn925Asn;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	24424	24424	.	+	.	ID=ID_175;Name=Q954H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A2862T;aa_name=p.Q954H;hgvs_nt=NC_045512.2:g.2862A>T;hgvs_aa=YP_009724390.1:p.Gln954His;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	24469	24469	.	+	.	ID=ID_176;Name=N969K;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=A;nt_name=g.T2907A;aa_name=p.N969K;hgvs_nt=NC_045512.2:g.2907T>A;hgvs_aa=YP_009724390.1:p.Asn969Lys;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	24844	24844	.	+	.	ID=ID_177;Name=V1094V;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C3282T;aa_name=p.V1094V;hgvs_nt=NC_045512.2:g.3282C>T;hgvs_aa=YP_009724390.1:p.Val1094Val;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	24865	24865	.	+	.	ID=ID_178;Name=H1101H;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C3303T;aa_name=p.H1101H;hgvs_nt=NC_045512.2:g.3303C>T;hgvs_aa=YP_009724390.1:p.His1101His;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	25000	25000	.	+	.	ID=ID_179;Name=D1146D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C3438T;aa_name=p.D1146D;hgvs_nt=NC_045512.2:g.3438C>T;hgvs_aa=YP_009724390.1:p.Asp1146Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	25046	25046	.	+	.	ID=ID_180;Name=P1162S;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C3484T;aa_name=p.P1162S;hgvs_nt=NC_045512.2:g.3484C>T;hgvs_aa=YP_009724390.1:p.Pro1162Ser;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1;citation=Schmidt et al. (2021);comb_mutation=;function_description=Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	25337	25337	.	+	.	ID=ID_181;Name=D1259Y;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G3775T;aa_name=p.D1259Y;hgvs_nt=NC_045512.2:g.3775G>T;hgvs_aa=YP_009724390.1:p.Asp1259Tyr;hgvs_alias=n/a;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	25339	25339	.	+	.	ID=ID_182;Name=D1259D;alias=n/a;gene=S;protein_name=surface glycoprotein;protein_symbol=S;protein_id=YP_009724390.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C3777T;aa_name=p.D1259D;hgvs_nt=NC_045512.2:g.3777C>T;hgvs_aa=YP_009724390.1:p.Asp1259Asp;hgvs_alias=n/a;vcf_gene=S;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	25416	25416	.	+	.	ID=ID_183;Name=F8F;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C24T;aa_name=p.F8F;hgvs_nt=NC_045512.2:g.24C>T;hgvs_aa=YP_009724391.1:p.Phe8Phe;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	25433	25433	.	+	.	ID=ID_184;Name=T14N;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=C;Variant_seq=A;nt_name=g.C41A;aa_name=p.T14N;hgvs_nt=NC_045512.2:g.41C>A;hgvs_aa=YP_009724391.1:p.Thr14Asn;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	25452	25452	.	+	.	ID=ID_185;Name=I20I;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C60T;aa_name=p.I20I;hgvs_nt=NC_045512.2:g.60C>T;hgvs_aa=YP_009724391.1:p.Ile20Ile;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	25584	25584	.	+	.	ID=ID_186;Name=T64T;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C192T;aa_name=p.T64T;hgvs_nt=NC_045512.2:g.192C>T;hgvs_aa=YP_009724391.1:p.Thr64Thr;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	25660	25660	.	+	.	ID=ID_187;Name=V90F;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G268T;aa_name=p.V90F;hgvs_nt=NC_045512.2:g.268G>T;hgvs_aa=YP_009724391.1:p.Val90Phe;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	25888	25888	.	+	.	ID=ID_188;Name=S166P;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T496C;aa_name=p.S166P;hgvs_nt=NC_045512.2:g.496T>C;hgvs_aa=YP_009724391.1:p.Ser166Pro;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26060	26060	.	+	.	ID=ID_189;Name=T223I;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C668T;aa_name=p.T223I;hgvs_nt=NC_045512.2:g.668C>T;hgvs_aa=YP_009724391.1:p.Thr223Ile;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26111	26111	.	+	.	ID=ID_190;Name=P240L;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C719T;aa_name=p.P240L;hgvs_nt=NC_045512.2:g.719C>T;hgvs_aa=YP_009724391.1:p.Pro240Leu;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26146	26146	.	+	.	ID=ID_191;Name=S252P;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T754C;aa_name=p.S252P;hgvs_nt=NC_045512.2:g.754T>C;hgvs_aa=YP_009724391.1:p.Ser252Pro;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26199	26199	.	+	.	ID=ID_192;Name=T269T;alias=n/a;gene=ORF3a;protein_name=ORF3a protein;protein_symbol=ORF3a;protein_id=YP_009724391.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G807T;aa_name=p.T269T;hgvs_nt=NC_045512.2:g.807G>T;hgvs_aa=YP_009724391.1:p.Thr269Thr;hgvs_alias=n/a;vcf_gene=ORF3a;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26270	26270	.	+	.	ID=ID_193;Name=T9I;alias=n/a;gene=E;protein_name=envelope protein;protein_symbol=E;protein_id=YP_009724392.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C26T;aa_name=p.T9I;hgvs_nt=NC_045512.2:g.26C>T;hgvs_aa=YP_009724392.1:p.Thr9Ile;hgvs_alias=n/a;vcf_gene=E;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1;citation=Borges et al. (2021);comb_mutation=;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26275	26275	.	+	.	ID=ID_194;Name=T11A;alias=n/a;gene=E;protein_name=envelope protein;protein_symbol=E;protein_id=YP_009724392.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A31G;aa_name=p.T11A;hgvs_nt=NC_045512.2:g.31A>G;hgvs_aa=YP_009724392.1:p.Thr11Ala;hgvs_alias=n/a;vcf_gene=E;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26526	26526	.	+	.	ID=ID_195;Name=A2S;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G4T;aa_name=p.A2S;hgvs_nt=NC_045512.2:g.4G>T;hgvs_aa=YP_009724393.1:p.Ala2Ser;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=immunosuppression variant emergence;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640888/;citation=Avanzato et al. (2020);comb_mutation=;function_description=Emergent as 16% variant by day 70 post-infection of female immunocompromised  individual with chronic lymphocytic leukemia and acquired hypogammaglobulinemia.  Variant became 100% in day 70 culture. Variant disappeared after convalescent plasma treatment (day 71) in subsequent patient sample sequencing.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26577	26577	.	+	.	ID=ID_196;Name=Q19E;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=G;nt_name=g.C55G;aa_name=p.Q19E;hgvs_nt=NC_045512.2:g.55C>G;hgvs_aa=YP_009724393.1:p.Gln19Glu;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26611	26611	.	+	.	ID=ID_197;Name=T30I;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C89T;aa_name=p.T30I;hgvs_nt=NC_045512.2:g.89C>T;hgvs_aa=YP_009724393.1:p.Thr30Ile;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26625	26625	.	+	.	ID=ID_198;Name=L35L;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C103T;aa_name=p.L35L;hgvs_nt=NC_045512.2:g.103C>T;hgvs_aa=YP_009724393.1:p.Leu35Leu;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26709	26709	.	+	.	ID=ID_199;Name=A63T;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=A;nt_name=g.G187A;aa_name=p.A63T;hgvs_nt=NC_045512.2:g.187G>A;hgvs_aa=YP_009724393.1:p.Ala63Thr;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26858	26858	.	+	.	ID=ID_200;Name=F112F;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C336T;aa_name=p.F112F;hgvs_nt=NC_045512.2:g.336C>T;hgvs_aa=YP_009724393.1:p.Phe112Phe;hgvs_alias=n/a;vcf_gene=M;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	26994	26994	.	+	.	ID=ID_201;Name=R158C;alias=n/a;gene=M;protein_name=membrane glycoprotein;protein_symbol=M;protein_id=YP_009724393.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=34;ao=1;dp=35;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C472T;aa_name=p.R158C;hgvs_nt=NC_045512.2:g.472C>T;hgvs_aa=YP_009724393.1:p.Arg158Cys;hgvs_alias=n/a;vcf_gene=M;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02857142857142857;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	27247	27247	.	+	.	ID=ID_202;Name=L16L;alias=n/a;gene=ORF6;protein_name=ORF6 protein;protein_symbol=ORF6;protein_id=YP_009724394.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C46T;aa_name=p.L16L;hgvs_nt=NC_045512.2:g.46C>T;hgvs_aa=YP_009724394.1:p.Leu16Leu;hgvs_alias=n/a;vcf_gene=ORF6;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	27259	27259	.	+	.	ID=ID_203;Name=R20R;alias=n/a;gene=ORF6;protein_name=ORF6 protein;protein_symbol=ORF6;protein_id=YP_009724394.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=C;nt_name=g.A58C;aa_name=p.R20R;hgvs_nt=NC_045512.2:g.58A>C;hgvs_aa=YP_009724394.1:p.Arg20Arg;hgvs_alias=n/a;vcf_gene=ORF6;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	27382	27382	.	+	.	ID=ID_204;Name=D61L;alias=n/a;gene=ORF6;protein_name=ORF6 protein;protein_symbol=ORF6;protein_id=YP_009724394.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=36;dp=37;sample_size=37;Reference_seq=GAT;Variant_seq=CTC;nt_name=g.GA181_182CT;aa_name=p.D61L;hgvs_nt=n/a;hgvs_aa=YP_009724394.1:p.Asp61Leu;hgvs_alias=n/a;vcf_gene=ORF6;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.972972972972973;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	mnp	27382	27382	.	+	.	ID=ID_204;Name=D61L;alias=n/a;gene=ORF6;protein_name=ORF6 protein;protein_symbol=ORF6;protein_id=YP_009724394.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1;dp=37;sample_size=37;Reference_seq=GAT;Variant_seq=CTT;nt_name=g.GAT181_183CTC;aa_name=p.D61L;hgvs_nt=n/a;hgvs_aa=YP_009724394.1:p.Asp61Leu;hgvs_alias=n/a;vcf_gene=ORF6;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	27426	27426	.	+	.	ID=ID_205;Name=T11T;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A33T;aa_name=p.T11T;hgvs_nt=NC_045512.2:g.33A>T;hgvs_aa=YP_009724395.1:p.Thr11Thr;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	27651	27651	.	+	.	ID=ID_206;Name=L86L;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=G;Variant_seq=A;nt_name=g.G258A;aa_name=p.L86L;hgvs_nt=NC_045512.2:g.258G>A;hgvs_aa=YP_009724395.1:p.Leu86Leu;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	27655	27655	.	+	.	ID=ID_207;Name=I88V;alias=n/a;gene=ORF7a;protein_name=ORF7a protein;protein_symbol=ORF7a;protein_id=YP_009724395.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A262G;aa_name=p.I88V;hgvs_nt=NC_045512.2:g.262A>G;hgvs_aa=YP_009724395.1:p.Ile88Val;hgvs_alias=n/a;vcf_gene=ORF7a;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	27807	27807	.	+	.	ID=ID_208;Name=L18L;alias=n/a;gene=ORF7b;protein_name=ORF7b;protein_symbol=ORF7b;protein_id=YP_009725318.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C52T;aa_name=p.L18L;hgvs_nt=NC_045512.2:g.52C>T;hgvs_aa=YP_009725318.1:p.Leu18Leu;hgvs_alias=n/a;vcf_gene=ORF7b;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	27915	27915	.	+	.	ID=ID_209;Name=G8X;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G22T;aa_name=p.G8X;hgvs_nt=NC_045512.2:g.22G>T;hgvs_aa=YP_009724396.1:p.Gly8Xaa;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=NONSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	27944	27944	.	+	.	ID=ID_210;Name=H17H;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C51T;aa_name=p.H17H;hgvs_nt=NC_045512.2:g.51C>T;hgvs_aa=YP_009724396.1:p.His17His;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	27995	27995	.	+	.	ID=ID_211;Name=D34D;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T102C;aa_name=p.D34D;hgvs_nt=NC_045512.2:g.102T>C;hgvs_aa=YP_009724396.1:p.Asp34Asp;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28077	28077	.	+	.	ID=ID_212;Name=V62L;alias=n/a;gene=ORF8;protein_name=ORF8 protein;protein_symbol=ORF8;protein_id=YP_009724396.1;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=G;Variant_seq=C;nt_name=g.G184C;aa_name=p.V62L;hgvs_nt=NC_045512.2:g.184G>C;hgvs_aa=YP_009724396.1:p.Val62Leu;hgvs_alias=n/a;vcf_gene=ORF8;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28271	28271	.	+	.	ID=ID_213;Name=g.A-3T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=T;nt_name=g.A-3T;aa_name=;hgvs_nt=NC_045512.2:g.3A>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=N;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28283	28283	.	+	.	ID=ID_214;Name=N4H;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=A;Variant_seq=C;nt_name=g.A10C;aa_name=p.N4H;hgvs_nt=NC_045512.2:g.10A>C;hgvs_aa=YP_009724397.2:p.Asn4His;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28296	28296	.	+	.	ID=ID_215;Name=N8S;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A23G;aa_name=p.N8S;hgvs_nt=NC_045512.2:g.23A>G;hgvs_aa=YP_009724397.2:p.Asn8Ser;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	mnp	28310	28310	.	+	.	ID=ID_216;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1;dp=37;sample_size=37;Reference_seq=CCC;Variant_seq=CTT;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=T cell evasion;source=https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1;citation=de Silva et al. (2021);comb_mutation=;function_description=Variant causes complete loss of T cell line responsiveness to B*27:05-restricted CD8+ N epitope QRNAPRITF 1-17(2,13).;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	mnp	28310	28310	.	+	.	ID=ID_216;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1;dp=37;sample_size=37;Reference_seq=CCC;Variant_seq=CTT;nt_name=g.C38T;aa_name=p.P13L;hgvs_nt=NC_045512.2:g.38C>T;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=homoplasy;source=https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1;citation=Borges et al. (2021);comb_mutation=;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	mnp	28310	28310	.	+	.	ID=ID_217;Name=P13F;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1;dp=37;sample_size=37;Reference_seq=CCC;Variant_seq=TTC;nt_name=g.CC37_38TT;aa_name=p.P13F;hgvs_nt=n/a;hgvs_aa=YP_009724397.2:p.Pro13Phe;hgvs_alias=n/a;vcf_gene=N;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28310	28310	.	+	.	ID=ID_216;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=35;dp=37;sample_size=37;Reference_seq=CCC;Variant_seq=CTC;nt_name=g.CC38_39TT;aa_name=p.P13L;hgvs_nt=n/a;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9459459459459459;function_category=T cell evasion;source=https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1;citation=de Silva et al. (2021);comb_mutation=;function_description=Variant causes complete loss of T cell line responsiveness to B*27:05-restricted CD8+ N epitope QRNAPRITF 1-17(2,13).;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28310	28310	.	+	.	ID=ID_216;Name=P13L;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=35;dp=37;sample_size=37;Reference_seq=CCC;Variant_seq=CTC;nt_name=g.CC38_39TT;aa_name=p.P13L;hgvs_nt=n/a;hgvs_aa=YP_009724397.2:p.Pro13Leu;hgvs_alias=n/a;vcf_gene=N;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.9459459459459459;function_category=homoplasy;source=https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1;citation=Borges et al. (2021);comb_mutation=;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent.;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28350	28350	.	+	.	ID=ID_218;Name=S26N;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=G;Variant_seq=A;nt_name=g.G77A;aa_name=p.S26N;hgvs_nt=NC_045512.2:g.77G>A;hgvs_aa=YP_009724397.2:p.Ser26Asn;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	28362	28362	.	+	.	ID=ID_219;Name=G30_S33delinsA;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=1;dp=37;sample_size=37;Reference_seq=GAGAACGCAG;Variant_seq=C;nt_name=g.GAGAACGCAG89_98C;aa_name=p.G30_S33delinsA;hgvs_nt=n/a;hgvs_aa=YP_009724397.2:p.Gly30_Ser33delinsAla;hgvs_alias=n/a;vcf_gene=N;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	28362	28362	.	+	.	ID=ID_220;Name=E31_S33del;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=36;dp=37;sample_size=37;Reference_seq=GAGAACGCAG;Variant_seq=G;nt_name=g.90_98delAGAACGCAG;aa_name=p.E31_S33del;hgvs_nt=NC_045512.2:g.90_98del;hgvs_aa=YP_009724397.2:p.Glu31_Ser33del;hgvs_alias=n/a;vcf_gene=N;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.972972972972973;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28438	28438	.	+	.	ID=ID_221;Name=A55A;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T165C;aa_name=p.A55A;hgvs_nt=NC_045512.2:g.165T>C;hgvs_aa=YP_009724397.2:p.Ala55Ala;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28507	28507	.	+	.	ID=ID_222;Name=S78S;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C234T;aa_name=p.S78S;hgvs_nt=NC_045512.2:g.234C>T;hgvs_aa=YP_009724397.2:p.Ser78Ser;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28674	28674	.	+	.	ID=ID_223;Name=A134V;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C401T;aa_name=p.A134V;hgvs_nt=NC_045512.2:g.401C>T;hgvs_aa=YP_009724397.2:p.Ala134Val;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28744	28744	.	+	.	ID=ID_224;Name=I157I;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C471T;aa_name=p.I157I;hgvs_nt=NC_045512.2:g.471C>T;hgvs_aa=YP_009724397.2:p.Ile157Ile;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28754	28754	.	+	.	ID=ID_225;Name=L161F;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C481T;aa_name=p.L161F;hgvs_nt=NC_045512.2:g.481C>T;hgvs_aa=YP_009724397.2:p.Leu161Phe;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	complex	28881	28881	.	+	.	ID=ID_226;Name=RG203KR;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=GGG;Variant_seq=AAC;nt_name=g.GGG608_610AAC;aa_name=p.RG203KR;hgvs_nt=n/a;hgvs_aa=YP_009724397.2:p.ArgGly203LysArg;hgvs_alias=n/a;vcf_gene=N;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	28916	28916	.	+	.	ID=ID_227;Name=G215S;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=G;Variant_seq=A;nt_name=g.G643A;aa_name=p.G215S;hgvs_nt=NC_045512.2:g.643G>A;hgvs_aa=YP_009724397.2:p.Gly215Ser;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	29059	29059	.	+	.	ID=ID_228;Name=R262R;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=T;Variant_seq=C;nt_name=g.T786C;aa_name=p.R262R;hgvs_nt=NC_045512.2:g.786T>C;hgvs_aa=YP_009724397.2:p.Arg262Arg;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	29095	29095	.	+	.	ID=ID_229;Name=F274F;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=35;ao=2;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C822T;aa_name=p.F274F;hgvs_nt=NC_045512.2:g.822C>T;hgvs_aa=YP_009724397.2:p.Phe274Phe;hgvs_alias=n/a;vcf_gene=N;mutation_type=SILENT;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.05405405405405406;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	29282	29282	.	+	.	ID=ID_230;Name=I337V;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=A;Variant_seq=G;nt_name=g.A1009G;aa_name=p.I337V;hgvs_nt=NC_045512.2:g.1009A>G;hgvs_aa=YP_009724397.2:p.Ile337Val;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	29409	29409	.	+	.	ID=ID_231;Name=T379I;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=C;Variant_seq=T;nt_name=g.C1136T;aa_name=p.T379I;hgvs_nt=NC_045512.2:g.1136C>T;hgvs_aa=YP_009724397.2:p.Thr379Ile;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=homoplasy;source=https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1;citation=Borges et al. (2021);comb_mutation=;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent.;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	29510	29510	.	+	.	ID=ID_232;Name=S413R;alias=n/a;gene=N;protein_name=nucleocapsid phosphoprotein;protein_symbol=N;protein_id=YP_009724397.2;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=37;dp=37;sample_size=37;Reference_seq=A;Variant_seq=C;nt_name=g.A1237C;aa_name=p.S413R;hgvs_nt=NC_045512.2:g.1237A>C;hgvs_aa=YP_009724397.2:p.Ser413Arg;hgvs_alias=n/a;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	snp	29543	29543	.	+	.	ID=ID_233;Name=g.G-15T;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=36;ao=1;dp=37;sample_size=37;Reference_seq=G;Variant_seq=T;nt_name=g.G-15T;aa_name=;hgvs_nt=NC_045512.2:g.15G>T;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=ORF10;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.02702702702702703;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
NC_045512.2	.	del	29733	29733	.	+	.	ID=ID_234;Name=g.CGAGGCCACGCGGAGTACGATCGAGTG29733C;alias=n/a;gene=intergenic;protein_name=n/a;protein_symbol=n/a;protein_id=n/a;ps_filter=n/a;ps_exc=n/a;mat_pep=n/a;mat_pep_desc=n/a;mat_pep_acc=n/a;ro=0;ao=17;dp=17;sample_size=37;Reference_seq=CGAGGCCACGCGGAGTACGATCGAGTG;Variant_seq=C;nt_name=g.CGAGGCCACGCGGAGTACGATCGAGTG29733C;aa_name=;hgvs_nt=n/a;hgvs_aa=n/a;hgvs_alias=n/a;vcf_gene=intergenic;mutation_type=;viral_lineage=XBB.1.17.1;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;variant=Omicron;variant_type=VOC;voi_designation_date=;voc_designation_date=26-Nov-2021;vum_designation_date=24-Nov-2021;status=actively_circulating;
